Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder.

Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N, Jessen T, Colbran RJ, Caron MG, Javitch JA, Blakely RD, Galli A.

J Neurosci. 2010 Apr 28;30(17):6048-57. doi: 10.1523/JNEUROSCI.5094-09.2010.

2.

ADHD and the dopamine transporter: are there reasons to pay attention?

Mazei-Robinson MS, Blakely RD.

Handb Exp Pharmacol. 2006;(175):373-415. Review.

PMID:
16722244
3.

Good riddance to dopamine: roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders.

Gowrishankar R, Hahn MK, Blakely RD.

Neurochem Int. 2014 Jul;73:42-8. doi: 10.1016/j.neuint.2013.10.016. Epub 2013 Nov 11. Review.

PMID:
24231471
4.

The dopamine transporter: a vigilant border control for psychostimulant action.

Williams JM, Galli A.

Handb Exp Pharmacol. 2006;(175):215-32. Review.

PMID:
16722238
5.

Mechanisms of dopamine transporter regulation in normal and disease states.

Vaughan RA, Foster JD.

Trends Pharmacol Sci. 2013 Sep;34(9):489-96. doi: 10.1016/j.tips.2013.07.005. Epub 2013 Aug 20. Review.

6.

Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.

Mergy MA, Gowrishankar R, Davis GL, Jessen TN, Wright J, Stanwood GD, Hahn MK, Blakely RD.

Neurochem Int. 2014 Jul;73:56-70. doi: 10.1016/j.neuint.2013.11.009. Epub 2013 Dec 8. Review.

7.

Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.

Wilens TE.

J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S46-53. doi: 10.1097/JCP.0b013e318173312f. Review.

PMID:
18480677
8.

Dopamine release mediated by the dopamine transporter, facts and consequences.

Leviel V.

J Neurochem. 2011 Aug;118(4):475-89. doi: 10.1111/j.1471-4159.2011.07335.x. Epub 2011 Jul 1. Review.

9.

Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD).

Oades RD.

Prog Brain Res. 2008;172:543-65. doi: 10.1016/S0079-6123(08)00926-6. Review.

PMID:
18772050
10.

Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE.

Pharmacol Rev. 2015 Oct;67(4):1005-24. doi: 10.1124/pr.114.010397. Review.

11.

Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse.

Zhu J, Reith ME.

CNS Neurol Disord Drug Targets. 2008 Nov;7(5):393-409. Review.

12.

The dopamine transporter and attention-deficit/hyperactivity disorder.

Madras BK, Miller GM, Fischman AJ.

Biol Psychiatry. 2005 Jun 1;57(11):1397-409. Epub 2005 Jan 5. Review.

PMID:
15950014
13.

Palmitoylation mechanisms in dopamine transporter regulation.

Rastedt DE, Vaughan RA, Foster JD.

J Chem Neuroanat. 2017 Oct;83-84:3-9. doi: 10.1016/j.jchemneu.2017.01.002. Epub 2017 Jan 20. Review.

PMID:
28115272
14.

Dopamine transporter mutant mice in experimental neuropharmacology.

Gainetdinov RR.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):301-13. Epub 2007 Dec 5. Review.

PMID:
18057916
15.

Positron emission tomography neuroimaging for a better understanding of the biology of ADHD.

Zimmer L.

Neuropharmacology. 2009 Dec;57(7-8):601-7. doi: 10.1016/j.neuropharm.2009.08.001. Epub 2009 Aug 13. Review.

PMID:
19682469
16.

The dopaminergic system in attention deficit/hyperactivity disorder.

Ohno M.

Congenit Anom (Kyoto). 2003 Jun;43(2):114-22. Review.

PMID:
12893970
17.

Behavioural and neurochemical abnormalities in mice lacking functional tachykinin-1 (NK1) receptors: a model of attention deficit hyperactivity disorder.

Yan TC, Hunt SP, Stanford SC.

Neuropharmacology. 2009 Dec;57(7-8):627-35. doi: 10.1016/j.neuropharm.2009.08.021. Epub 2009 Sep 10. Review.

PMID:
19748515
18.

Neuron membrane trafficking and protein kinases involved in autism and ADHD.

Kitagishi Y, Minami A, Nakanishi A, Ogura Y, Matsuda S.

Int J Mol Sci. 2015 Jan 30;16(2):3095-115. doi: 10.3390/ijms16023095. Review.

19.

The role of human dopamine transporter in NeuroAIDS.

Zhu J, Ananthan S, Zhan CG.

Pharmacol Ther. 2017 Oct 4. pii: S0163-7258(17)30244-9. doi: 10.1016/j.pharmthera.2017.10.007. [Epub ahead of print] Review.

PMID:
28987321
20.

Immunomodulatory Effects Mediated by Dopamine.

Arreola R, Alvarez-Herrera S, Pérez-Sánchez G, Becerril-Villanueva E, Cruz-Fuentes C, Flores-Gutierrez EO, Garcés-Alvarez ME, de la Cruz-Aguilera DL, Medina-Rivero E, Hurtado-Alvarado G, Quintero-Fabián S, Pavón L.

J Immunol Res. 2016;2016:3160486. Epub 2016 Oct 4. Review.

Supplemental Content

Support Center